ClinicalTrials.gg
Sign In

Biological

Vibostolimab/Pembrolizumab MK-7684A clinical trials

Also written MK-7684A.

studies test it
8
open now
0
in phase 3
1
first study started
2016

How studies write it

Studies that test it under each name

Name

Pembrolizumab/Vibostolimab coformulation
4
Pembrolizumab/Vibostolimab Co-Formulation
2

Development codes

MK-7684A
8

Studies by the year they started

8 studies that test it; most in 2016 (3)

Studies that test Vibostolimab/Pembrolizumab MK-7684A, by start year
YearStudies
20163
20201
20212
20221
20231

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
6
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Small Cell Lung Carcinoma
1
Uterine Cervical Neoplasms
1
Carcinoma, Renal Cell
1
Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Urinary Bladder Neoplasms
1

Who runs them

Industry 8 · Other 0

Merck Sharp & Dohme LLC (8)

Often tested with

Tested in the same studies.

Pembrolizumab (4) · Belzutifan (2) · Carboplatin (1) · Etoposide (1) · Favezelimab/Pembrolizumab Formulation (1) · Favezelimab (1) · Lenvatinib (1) · Pembrolizumab/Quavonlimab MK-1308A (1)

Studies

Open first, then newest update. How each study uses Vibostolimab/Pembrolizumab MK-7684A is read from its arms, and is right about nine times in ten.

Testing it · 8